Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate superiority of 500 mg and 250 mg Aspirin® i.v. (BAY 81-8781) treatment over oral treatment with 300 mg Aspirin® N tablets to inhibit thromboxane A2-release (measured as stable metabolite thromboxane B2 in serum, TXB2) at 5 minutes after single dose of study drug administration. Thromboxane release is a surrogate parameter for the inhibition of platelet aggregation and thrombus formation in vivo
Critère d'inclusion
- Acute coronary syndrome (ACS)